The Journal for ImmunoTherapy of Cancer (JITC) is a leading, peer-reviewed, open-access journal dedicated to the science and clinical application of cancer immunotherapy. It provides a high-profile platform for cutting-edge research on tumor immunotherapy, exploring novel strategies to harness the power of the immune system to fight cancer.
This journal covers a broad spectrum of topics, including basic and translational research, clinical trials, and therapeutic advances in cancer immunology. Key areas of focus include tumor microenvironment, clinical oncology, immunology, and the development of innovative vaccines and antiviral therapy approaches. Indexed in major databases, the JITC reaches a global audience of researchers, clinicians, and industry professionals committed to advancing the field of cancer immunotherapy.
JITC aims to accelerate the translation of scientific discoveries into effective cancer treatments. By providing a forum for disseminating high-quality research and fostering collaboration, the journal strives to improve outcomes for cancer patients worldwide, contributing to innovative progress and transformative breakthroughs in oncological care.